This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Creanga AA, Catalano PM, Bateman BT. Obesity in Pregnancy. N Engl J Med. 2022;387:248–59.
Seneviratne SN, Rajindrajith S. Fetal programming of obesity and type 2 diabetes. World J Diabetes. 2022;13:482–97.
Hoek A, Wang Z, van Oers AM, Groen H, Cantineau AEP. Effects of preconception weight loss after lifestyle intervention on fertility outcomes and pregnancy complications. Fertil Steril. 2022;118:456–62.
Shawe J, Ceulemans D, Akhter Z, Neff K, Hart K, Heslehurst N, et al. Pregnancy after bariatric surgery: Consensus recommendations for periconception, antenatal and postnatal care. Obes Rev. 2019;20:1507–22.
Schultes B. Pharmacological Interventions against Obesity: Current Status and Future Directions. Visc Med. 2016;32:347–51.
Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325:1414–25.
Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24:1553–64.
Graham DL, Madkour HS, Noble BL, Schatschneider C, Stanwood GD. Long-term functional alterations following prenatal GLP-1R activation. Neurotoxicol Teratol. 2021;87:106984.
Younes ST, Maeda KJ, Sasser J, Ryan MJ. The glucagon-like peptide 1 receptor agonist liraglutide attenuates placental ischemia-induced hypertension. Am J Physiol Heart Circ Physiol. 2020;318:H72–7.
Novo Nordisk Canada Inc. Product Monograph including patient medication information. Saxenda. Liraglutide 6mg/mL. [cited 2022 Dec 31] https://www.novonordisk.ca/content/dam/nncorp/ca/en/products/Saxenda%20PM%20English%20-%20Marketed%20-%2025%20February%202021.pdf.
Author information
Authors and Affiliations
Contributions
Conceiving the work that led to the submission: BS, BE, KT, JP, GR. Drafting the paper: BS, BE, KT, JP, GR. Revising paper: BS, BE, JP, KT. All authors read and approved the final version of the paper.
Corresponding author
Ethics declarations
Competing interests
Dr BS has received presentation fees from and compensation as a member of a scientific advisory board of Novo Nordisk and Eli Lilly as well as for serving as a study investigator for Novo Nordisk. Dr BE has nothing to declare. Dr KT has received presentation fees from and compensation as a member of a scientific advisory board of Novo Nordisk. She also received a restricted research grant from Novo Nordisk. Dr JP has received compensation as a member of a scientific advisory board of Eli Lilly and received a unrestricted educational grant from Novo Nordisk. Dr GR has received presentation fees from and compensation as a member of a scientific advisory board of Novo Nordisk and Eli Lilly as well as for serving as a study investigator for Novo Nordisk.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Schultes, B., Ernst, B., Timper, K. et al. Pharmacological interventions for weight loss before conception—putative effects on subsequent gestational weight gain should be considered. Int J Obes 47, 335–337 (2023). https://doi.org/10.1038/s41366-023-01276-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41366-023-01276-7
This article is cited by
-
What is the evidence regarding the safety of new obesity pharmacotherapies
International Journal of Obesity (2024)